🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
LENSAR, Inc. (LNSR)
NASDAQ: LNSR · Real-Time Price · USD
4.460
-0.180 (-3.88%)
At close: Nov 20, 2026, 4:00 PM EST
4.490
+0.030 (0.67%)
After-hours: Nov 20, 2026, 4:10 PM EST

Company Description

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally.

The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.

It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room.

LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

LENSAR, Inc.
LENSAR logo
CountryUnited States
Founded2004
IndustryMedical Devices
SectorHealthcare
Employees150
CEONicholas Curtis

Contact Details

Address:
2800 Discovery Drive
Orlando, Florida 32826
United States
Phone888 536 7271
Websitelensar.com

Stock Details

Ticker SymbolLNSR
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code1320350
CUSIP Number52634L108
ISIN NumberUS52634L1089
Employer ID32-0125724
SIC Code3841

Key Executives

NamePosition
Nicholas T. CurtisPresident, Chief Executive Officer and Director
Alan B. ConnaughtonChief Operating Officer
Michael A. RossiInterim Chief Financial Officer and Principal Financial Officer and Secretary
Kendra W. WongPrincipal Accounting Officer

Latest SEC Filings

DateTypeTitle
Nov 18, 2026144Filing
Nov 17, 2026144Filing
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 10, 202610-QQuarterly Report
Nov 10, 20268-KCurrent Report
Aug 13, 202610-QQuarterly Report
Aug 13, 20268-KCurrent Report
Aug 10, 20268-KCurrent Report
Jul 29, 2026SCHEDULE 13G/AFiling
Jun 23, 2026DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides